Baebies

• Booth: 5127

Baebies' vision is to provide a healthy start for all. We deliver innovative products for newborn screening & pediatric testing powered by digital microfluidics. Baebies has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its rapid, point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. The test is run on the FINDER® platform, using a 50 µL blood sample (one drop of blood), FINDER delivers results approximately 15 minutes after sample introduction.

 Press Releases

• Baebies Receives FDA Breakthrough Device Designation for First Point-of-Car (May 12, 2025)
  Baebies has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER^® platform—the first point-of-care heparin monitoring assay. Designed for patients receiving unfractionated or low molecular weight heparin, the test provides results in under 15 minutes from just 50 µL of whole blood. This designation recognizes the test’s potential to bring heparin monitoring closer to the patient, enabling faster and more effective dose management in critical care settings. 

• Baebies Expands Its Vision: Any Test, Anywhere, Everyone™ (May 12, 2025)

  After delivering more than 22 million healthy starts, Baebies—like all babies do—has grown. What began with a focus on newborn screening has now expanded to cover diagnostics for all ages, recognizing that our technology is just as impactful for adults as it is for infants.

  Our mission has evolved from “everyone deserves a healthy start” to everyone deserves to be healthy, where any test can be taken anywhere, for everyone.